SEOUL (Reuters) – A South Korean court has suspended the financial regulator’s disciplinary action against Samsung (KS:) BioLogics Co Ltd (KS:) over breach of accounting rules, an official at the Seoul Administrative Court said on Tuesday.
Samsung BioLogics filed an administrative lawsuit to overturn the watchdog’s ruling on accounting violations and sought a court injunction to restrain the disciplinary action until the court reaches a conclusion.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.